HDAC1 and hepatocellular carcinoma: Our integrative in silico analysis revealed that Nirmatrelvir, which was originally developed as an antiviral agent, may exhibit previously unrecognized inhibitory activity against HDAC1 and HDAC3, which are critical epigenetic regulators in HCC.